Cytidine Deaminase Inhibitors (CDA) - Pipeline Insight, 2024

This “Cytidine Deaminase Inhibitors (CDA) - Pipeline Insight, 2024” report provides comprehensive insights about 2+ companies and 3+ pipeline drugs in Cytidine Deaminase Inhibitors (CDA) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Cytidine Deaminase Inhibitors (CDA) Understanding

Cytidine Deaminase Inhibitors (CDA): Overview

Cytidine deaminase inhibitors are molecules that inhibit the activity of the enzyme cytidine deaminase. Cytidine deaminase is an evolutionarily conserved enzyme of the pyrimidine salvage pathway. It catalyzes the hydrolytic deamination of cytidine and deoxycytidine to form uridine and deoxyuridine, respectively. Human cytidine deaminase (CDA) is an enzyme prominent for its role in catalyzing metabolic processing of nucleoside-type anticancer and antiviral agents. It is thus a promising target for the development of small molecule therapeutic adjuvants. Cytidine deaminase inhibitors are considered as a potential and promising treatment for tumors with highly expressed CDA.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cytidine Deaminase Inhibitors (CDA) R&D. The therapies under development are focused on novel approaches for Cytidine Deaminase Inhibitors (CDA).

Cytidine Deaminase Inhibitors (CDA) Emerging Drugs Chapters

This segment of the Cytidine Deaminase Inhibitors (CDA) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cytidine Deaminase Inhibitors (CDA) Emerging Drugs

ASTX727: Astex Pharmaceuticals ASTX727 is a novel, orally administered fixed dose combination of cedazuridine, an inhibitor of cytidine deaminase, with the anti-cancer DNA hypomethylating agent, decitabine. By inhibiting cytidine deaminase, cedazuridine inhibits the major mechanism by which decitabine is degraded in the gut and liver, and the combination therefore permits the efficient delivery of decitabine orally.

Cytidine Deaminase Inhibitors (CDA): Therapeutic Assessment

This segment of the report provides insights about the different Cytidine Deaminase Inhibitors (CDA) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Cytidine Deaminase Inhibitors (CDA)

There are approx. 2+ key companies which are developing the Cytidine Deaminase Inhibitors (CDA). The companies which have their Cytidine Deaminase Inhibitors (CDA) drug candidates in the most advanced stage, i.e. Phase III include, Astex Pharmaceuticals.

Phases

This report covers around 3+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Cytidine Deaminase Inhibitors (CDA) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cytidine Deaminase Inhibitors (CDA): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cytidine Deaminase Inhibitors (CDA) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cytidine Deaminase Inhibitors (CDA) drugs.

Cytidine Deaminase Inhibitors (CDA) Report Insights

• Cytidine Deaminase Inhibitors (CDA) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cytidine Deaminase Inhibitors (CDA) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Cytidine Deaminase Inhibitors (CDA) drugs?
• How many Cytidine Deaminase Inhibitors (CDA) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Cytidine Deaminase Inhibitors (CDA)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cytidine Deaminase Inhibitors (CDA) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cytidine Deaminase Inhibitors (CDA) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Astex Pharmaceuticals
• Novo Nordisk

Key Products

• ASTX727
• Decitabine/tetrahydrouridine
• ASTX-030